SECRETION OF SOLUBLE FACTORS BY AML CELLS INFLUENCE CD33/CD3 BITE® ANTIBODY MEDIATED CYTOTOXICITY AND T-CELL PROLIFERATION

被引：0
|
作者：
Costanzi, M. [1 ,2 ]
Krupka, C. [1 ,2 ]
Kischel, R. [3 ]
Kufer, P. [3 ]
Koehnke, T. [1 ,2 ]
Spiekermann, K. [2 ,4 ,5 ]
Hiddemann, W. [2 ,4 ,5 ]
Subklewe, M. [1 ,2 ,4 ,5 ]
机构：
[1] Hosp Ludwig Maximilians Univ LMU, Gene Ctr, Lab Translat Canc Immunol, Munich, Germany
[2] Hosp Ludwig Maximilians Univ LMU, Dept Internal Med 3, Munich, Germany
[3] AMGEN Res GmbH, Munich, Germany
[4] German Canc Consortium DKTK, Heidelberg, Germany
[5] German Canc Res Ctr, Heidelberg, Germany
来源：
HAEMATOLOGICA | 2017年 / 102卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
E867
引用
收藏
页码：357 / 358
页数：2
相关论文
共 50 条
  • [41] The CD64/CD28/CD3ζ chimeric receptor reprograms T-cell metabolism and promotes T-cell persistence and immune functions while triggering antibody-independent and antibody-dependent cytotoxicity
    Caratelli, Sara
    De Paolis, Francesca
    Silvestris, Domenico Alessandro
    Baldari, Silvia
    Salvatori, Illari
    Tullo, Apollonia
    Lanzilli, Giulia
    Gurtner, Aymone
    Ferri, Alberto
    Valle, Cristiana
    Padovani, Simona
    Cesarini, Valeriana
    Sconocchia, Tommaso
    Cifaldi, Loredana
    Arriga, Roberto
    Spagnoli, Giulio Cesare
    Ferrone, Soldano
    Venditti, Adriano
    Rossi, Piero
    Pesole, Graziano
    Toietta, Gabriele
    Sconocchia, Giuseppe
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2025, 14 (01)
  • [42] RECEPTOR-MEDIATED GENE-TRANSFER INTO HUMAN T-LYMPHOCYTES VIA BINDING OF DNA/CD3 ANTIBODY PARTICLES TO THE CD3 T-CELL RECEPTOR COMPLEX
    BUSCHLE, M
    COTTEN, M
    KIRLAPPOS, H
    MECHTLER, K
    SCHAFFNER, G
    ZAUNER, W
    BIRNSTIEL, ML
    WAGNER, E
    HUMAN GENE THERAPY, 1995, 6 (06) : 753 - 761
  • [43] Preclinical validation of a novel CD133/CD3 bispecific T -cell engager (BiTE) antibody to target patient -derived glioblastoma cells
    Vora, Parvez
    Venugopal, Chitra
    Adams, Jarrett
    Pan, James
    Chokshi, Chirayu
    Qazi, Maleeha
    Subapanditha, Minomi
    Singh, Mohini
    Bakhshinyan, David
    Bezverbnaya, Ksenia
    McFarlane, Nicole
    Bramson, Jonathan
    Sidhu, Sachdev
    Moffat, Jason
    Singh, Sheila
    CANCER RESEARCH, 2016, 76
  • [44] A DUAL TARGETING CD33/CD123 NANOBODY® T-CELL ENGAGER WITH POTENT ANTI-AML ACTIVITY AND A MANAGEABLE SAFETY PROFILE
    Dullaers, Melissa
    Deschamps, Geert
    Bonnevaux, Helene
    Guerif, Stephane
    De Brabandere, Veronique
    Amara, Celine
    Brige, Ann
    Dejonckheere, Eline
    Virone-Oddos, Angela
    Chiron, Marielle
    Roobrouck, Annelies
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1242 - A1242
  • [45] CD33-BiTE® antibody construct mediated lysis of AML cells is influenced by the choice of the pretherapeutic cytoreductive agent in vitro
    Brauneck, F.
    Krupka, C.
    Lichtenegger, F. S.
    Kufer, P.
    Kischel, R.
    Zugmaier, G.
    Koehnke, T.
    Altmann, T.
    Schneider, S.
    Fiegl, M.
    Spiekermann, K.
    Hiddemann, W.
    Subklewe, M.
    Oncology Research and Treatment, 2015, 38 : 48 - 48
  • [46] T-cell mediated lysis of prostate cancer cells with a single-chain PSMA/CD3 bispecific antibody construct.
    Elsaesser-Beile, Ursula
    Buehler, Patrick
    Wolf, Philipp
    Katzenwadel, Arndt
    Wetterauer, Ulrich
    TUMOR BIOLOGY, 2006, 27
  • [47] Phase 1 First-in-Human Trial of AMV564, a Bivalent Bispecific (2:2) CD33/CD3 T-Cell Engager, in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
    Westervelt, Peter
    Cortes, Jorge E.
    Altman, Jessica K.
    Long, Meixiao
    Oehler, Vivian G.
    Gojo, Ivana
    Guenot, Jeanmarie
    Chun, Patrick
    Roboz, Gail J.
    BLOOD, 2019, 134
  • [48] T-CELL ACTIVATION BY CROSS-LINKING AN ANTI CD3 ANTIBODY WITH A 2ND ANTI T-CELL ANTIBODY
    PICHLER, WJ
    WALKER, C
    BETTENS, F
    IMMUNOBIOLOGY, 1987, 175 (04) : 269 - 269
  • [49] Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    Wu, Jingjing
    Fu, Jiaping
    Zhang, Mingzhi
    Liu, Delong
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2015, 8
  • [50] Blinatumomab: a bispecific T cell engager (BiTE) antibody against CD19/CD3 for refractory acute lymphoid leukemia
    Jingjing Wu
    Jiaping Fu
    Mingzhi Zhang
    Delong Liu
    Journal of Hematology & Oncology, 8
12345